Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments (NCT04893525)
Evaluating Microdosing in Emergency Departments: A Randomized Controlled Trial Comparing the Effectiveness of Buprenorphine/Naloxone Microdosing vs. Standard Dosing (EMED Study)
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-centre, open-label RCT at four Emergency Departments (EDs) in British Columbia and Alberta. The purpose of the current study is to compare the effectiveness of buprenorphine/naloxone microdosing and standard dosing take-home induction regimens at enabling patients to successfully complete the induction regimen, and at retaining patients on opioid agonist therapy. We will randomize our enrolled patients to receive take-home microdosing or standard dosing packages of buprenorphine/naloxone. For the microdosing arm, patients immediately start taking low doses that increase to effective levels without requiring them to go into withdrawal. We hypothesize that ED patients provided buprenorphine/naloxone microdosing packages will be more likely to successfully complete the induction period compare to patients provided standard dosing packages. We furthermore hypothesize that those provided microdosing will be more likely to be retained in opioid agonist therapy, and will experience lower overdose, mortality, and healthcare utilization subsequent to their ED visit.
Who can join: Review the eligibility criteria below.
Location: Foothills Medical Centre — Calgary, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Foothills Medical Centre — Calgary, Alberta
- Northeast Community Health Centre — Edmonton, Alberta
- Royal Alexandra Hospital — Edmonton, Alberta
- Vancouver General Hospital — Vancouver, British Columbia
- University of British Columbia Hospital — Vancouver, British Columbia
- St. Paul's Hospital — Vancouver, British Columbia
📞 Contact the Study Coordinator
Phone: (604) 615-2538
Email: seth.long@ubc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Opioid-use Disorder
- Recovery Management Checkups for Opioid Use Disorder Experiment — Chicago, Illinois
- Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder — Philadelphia, Pennsylvania
- Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment — The Bronx, New York
- Neuromodulation and Cognitive Training in Opioid Use Disorder — Minneapolis, Minnesota
- Pilot Research on Opioid Use Disorder — San Francisco, California
- Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With PrEP Adherence and Support Services — Bridgeport, Connecticut
Explore by condition: All Opioid-use Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.